Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979635 | 1.00 | EPHA2 (0.44) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL18313454 | 0.90 | SLC22A2 (0.40) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL19986942 | 0.85 | EPHA2 (0.47) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL29980049 | 0.85 | EPHA2 (0.47) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL21292591 | 0.84 | LMNA (0.46) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL19987032 | 0.84 | LMNA (0.46) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL21292590 | 0.84 | LMNA (0.46) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL21292601 | 0.83 | LMNA (0.43) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL19987095 | 0.83 | LMNA (0.43) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL19987149 | 0.83 | LMNA (0.43) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-18 | — | — | US | disclosed |
| CN-109689656-B | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| WO-2018050510-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296298-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | EPHA2 4336/4885FLT4 1268/4885GSK3B 3869/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | EPHA2 4336/4885FLT4 1268/4885GSK3B 3869/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | EPHA2 4336/4885FLT4 1268/4885GSK3B 3869/4885 |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | EPHA2 4336/4885FLT4 1268/4885GSK3B 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.